… descriptive, multicentre, and observational cohort study conducted in GH in France. … cohort.
Despite their low cerebrospinal fluid penetration rate (2.5 to 13% for erlotinib, 1% for gefitinib […

… to the first-generation TKI erlotinib or gefitinib in the FLAURA study. In a post hoc analysis,
a … To our knowledge, this is one of the largest cohort studies from Western Europe reporting …

… cohorts [10,16]. In contrast, most such studies did observe PFS prolonging for study cohorts,
… in such clinical cases, with gefitinib/erlotinib being the baseline reference therapy for all …

… gefitinib, 1,599 erlotinib, and 1,512 afatinib) as first-line therapy were included in our study
(… To the best of our knowledge, this study is the single largest cohort study to investigate the …

… 2.1 Study Design This was a retrospective cohort study of linked health administrative
data in the province of Ontario, Canada. The datasets are housed at the Institute for Clinical …

… epidermal growth factor receptor (erlotinib, gefitinib, and afatinib), … cohort could later be
extended with 6 patients treated with 800 mg sunitinib every 2 weeks enrolled in a clinical study …

… have received first-line erlotinib, gefitinib, afatinib, or icotinib; … safety of tepotinib plus gefitinib
compared with chemotherapy in … Within the phase 2 study, an exploratory single-arm cohort …

… compared gefitinib plus chemotherapy with gefitinib in patients with untreated NSCLC
harboring EGFR mutations. This study compared the efficacy of chemotherapy alone and gefitinib …

… resistant to erlotinib, and cohort B enrolled erlotinib-naïve … In this study, we demonstrated
that standard-dose erlotinib … A study in Chinese patients with gefitinib plus capmatinib also …

… From May 2011 to December 2017, a total of 729 patients in NCKUH received afatinib,
erlotinib, or gefitinib as first-line therapies for EGFR mutation-positive advanced NSCLC. Among …